Doctoral Program for World-leading Innovative & Smart Education
Activity
[Press Release] Hiroshima University starts human trial of miRNA drug vs treatment-resistant cancer linked to asbestos
March 30, 2022
The team of Japanese scientists behind the anticancer miRNA drug, led by Professor Hidetoshi TAHARA, the director of the the Frontier Development Program for Genome Editing, has launched PURMX Therapeutics Co., Ltd. as a new venture of the university to carry out the clinical study.
The details are as follows: